Product category:
Genomics
News Release from: GE Healthcare | Subject: In Cell 3000
Edited by the Laboratorytalk Editorial
Team on 10 November 2003
Integrated cellular screening for drug
discovery
Eli Lilly has purchased an integrated suite of cellular screening technology and licences to help in the identification of potential therapeutics in its drug discovery programme
Amersham reports that Eli Lilly has purchased an integrated suite of cellular screening technology and licences to help in the identification of potential therapeutics in its drug discovery programme In addition to the purchase of an In Cell analyser 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria green fluorescent protein (GFP)
This article was originally published on Laboratorytalk on 12 May 2003 at 8.00am (UK)
Related stories
Norak buys second cell analyser
Chooses additional In Cell analyser to support internal drug discovery programme and a new screening collaboration business
Tips to improve radiochemical safety
Contains reaction-sized aliquots of radionucleotide in a solution-free format, making experiments easier and safer to do
20,000 human genes in a single experiment
Bioarray can be used to identify up or down regulated genes involved in key biological processes including oncogenesis, metabolism, inflammation and apoptosis
Furthermore, Lilly has secured rights to operate under BioImage's Redistribution patent portfolio for monitoring intracellular signalling pathways, including protein translocation.
Utilising the advanced imaging quality and speed of the In Cell 3000 system in conjunction with the Aequorea Victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context.
"We are delighted to be working with Lilly in this area," said Mike Evans, vice president marketing and strategy, discovery systems at Amersham Biosciences, "Lilly's decision to utilise GFP and Redistribution technology together with the In Cell 3000 reflects the trend in the pharmaceutical industry towards generating biological information earlier in the drug development process to speed up the time to market." "I am pleased that Lilly has chosen Redistribution to enhance its drug discovery program," said Patrik Dahlen, CEO of BioImage.
"We are proud to have contributed with the Redistribution technology and look forward to its further utilisation in drug discovery.".
• GE Healthcare: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
